KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call Transcript September 11, 2025KalVista Pharmaceuticals, Inc. misses on earnings expectations.
Kalvista Pharmaceuticals Inc. (KALV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 4,955,000 | $56,016,275 | +1% | 1.69% |
| 2. | Tang Capital Management Kevin C. Tang | 4,941,798 | $55,867,026 | 2.82% | |
| 3. | Vestal Point Capital Ryan Wilder | 4,675,000 | $52,850,875 | -2% | 2.78% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,920,664 | $21,713,107 | +19% | 0.11% |
| 5. | SilverArc Capital Devesh Gandhi | 1,832,171 | $20,712,693 | +8% | 3.82% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.42 | 25,000 | $235,500.00 | 5,303,985 | 2025-04-09 | Filing | |
| $9.33 | 61,700 | $575,661.00 | 5,278,985 | 2025-02-13 | Filing | |
| $9.23 | 100,000 | $923,000.00 | 5,217,285 | 2025-02-12 | Filing | |
| $9.18 | 26,703 | $245,133.54 | 5,117,285 | 2025-02-11 | Filing | |
| $9.14 | 4,137 | $37,812.18 | 5,090,582 | 2025-02-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.84 | 7,294 | $115,536.96 | 395,189 | 2025-09-08 | Filing | |
| $13.42 | 1,480 | $19,861.60 | 32,291 | 2025-08-25 | Filing | |
| $13.42 | 1,954 | $26,222.68 | 132,052 | 2025-08-25 | Filing | |
| $13.42 | 2,336 | $31,349.12 | 122,505 | 2025-08-25 | Filing | |
| $13.22 | 1,864 | $24,647.30 | 28,771 | 2025-08-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 176,583 | $2,150,781 | 0.08% | |
| 2. | 5,200 | $63,336 | 0% | |
| 3. | 4,557 | $55,504 | 0% | |
| 4. | 2,232 | $27,186 | 0% | |
| 5. | 1,590 | $19,366 | 0.01% |
News See All
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista Pharmaceuticals, Inc.
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts.
5 Best Micro Cap Stocks To Invest In
In this piece, we will take a look at the five best micro cap stocks to invest in.
Hedge Funds Are Buying KalVista Pharmaceuticals, Inc. (KALV)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Cashing Out Of KalVista Pharmaceuticals, Inc. (KALV)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
10 Pharmaceutical Stocks to Buy According to Timothy Lynch's Stonepine Capital
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch's Stonepine Capital.
Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV)
In this article we will take a look at whether hedge funds think KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a good investment right now.
Is KALV A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Hedge Fund Resource Center Billionaire Hedge Funds
